Clinical Trial Update: Ranolazine Mediated PVC Reduction in Ischemic Heart Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ranolazine for reduction of ventricular premature complexes in patients with ischemic heart disease has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Ischemia
• Ventricular Premature Complexes

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: Kent Hospital, Rhode Island | Conditions: Ventricular Premature Complexes, Myocardial Ischemia | Phase 2 | Status: COMPLETED | Results posted: 2020-01-29